Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe RNA Based Therapeutic Market, by Type
1.4.2 Europe RNA Based Therapeutic Market, by Application
1.4.3 Europe RNA Based Therapeutic Market, by End User
1.4.4 Europe RNA Based Therapeutic Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Acquisition and Mergers
3.2.3 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2017-2021)
3.3.2 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2017, Apr – 2022, Jan) Leading Players
Chapter 4. Europe RNA Based Therapeutic Market by Type
4.1 Europe RNA Antisense Market by Country
4.2 Europe RNA Interference (RNAi) Market by Country
Chapter 5. Europe RNA Based Therapeutic Market by Application
5.1 Europe Genetic disorders Market by Country
5.2 Europe Auto immune disorders Market by Country
Chapter 6. Europe RNA Based Therapeutic Market by End User
6.1 Europe Research Institutes Market by Country
6.2 Europe Hospitals & Clinics Market by Country
Chapter 7. Europe RNA Based Therapeutic Market by Country
7.1 Germany RNA Based Therapeutic Market
7.1.1 Germany RNA Based Therapeutic Market by Type
7.1.2 Germany RNA Based Therapeutic Market by Application
7.1.3 Germany RNA Based Therapeutic Market by End User
7.2 UK RNA Based Therapeutic Market
7.2.1 UK RNA Based Therapeutic Market by Type
7.2.2 UK RNA Based Therapeutic Market by Application
7.2.3 UK RNA Based Therapeutic Market by End User
7.3 France RNA Based Therapeutic Market
7.3.1 France RNA Based Therapeutic Market by Type
7.3.2 France RNA Based Therapeutic Market by Application
7.3.3 France RNA Based Therapeutic Market by End User
7.4 Russia RNA Based Therapeutic Market
7.4.1 Russia RNA Based Therapeutic Market by Type
7.4.2 Russia RNA Based Therapeutic Market by Application
7.4.3 Russia RNA Based Therapeutic Market by End User
7.5 Spain RNA Based Therapeutic Market
7.5.1 Spain RNA Based Therapeutic Market by Type
7.5.2 Spain RNA Based Therapeutic Market by Application
7.5.3 Spain RNA Based Therapeutic Market by End User
7.6 Italy RNA Based Therapeutic Market
7.6.1 Italy RNA Based Therapeutic Market by Type
7.6.2 Italy RNA Based Therapeutic Market by Application
7.6.3 Italy RNA Based Therapeutic Market by End User
7.7 Rest of Europe RNA Based Therapeutic Market
7.7.1 Rest of Europe RNA Based Therapeutic Market by Type
7.7.2 Rest of Europe RNA Based Therapeutic Market by Application
7.7.3 Rest of Europe RNA Based Therapeutic Market by End User
Chapter 8. Company Profiles
8.1 Arbutus Biopharma Corporation
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Research & Development Expenses
8.1.4 Recent strategies and developments:
8.1.4.1 Partnerships, Collaborations, and Agreements:
8.1.4.2 Acquisitions, Mergers and Joint Ventures:
8.2 Arrowhead Pharmaceuticals, Inc.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Research & Development Expenses
8.2.4 Recent strategies and developments:
8.2.4.1 Partnerships, Collaborations, and Agreements:
8.3 Benitec Biopharma, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Research & Development Expenses
8.4 Alnylam Pharmaceuticals, Inc.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Research & Development Expense
8.4.4 Recent strategies and developments:
8.4.4.1 Partnerships, Collaborations, and Agreements:
8.4.4.2 Approvals and Trials:
8.5 Sanofi S.A. (Sanofi Genzyme)
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expense
8.5.5 Recent strategies and developments:
8.5.5.1 Partnerships, Collaborations, and Agreements:
8.5.5.2 Acquisition and Mergers:
8.6 Biogen, Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Regional Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.7 Gradalis, Inc.
8.7.1 Company Overview
8.8 Ionis Pharmaceuticals, Inc.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental Analysis
8.8.4 Research & Development Expenses
8.8.5 Recent strategies and developments:
8.8.5.1 Partnerships, Collaborations, and Agreements:
8.9 Sarepta Therapeutics, Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Research & Development Expenses
8.9.4 Recent strategies and developments:
8.9.4.1 Partnerships, Collaborations, and Agreements:
8.10. Silence Therapeutics Plc
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Research & Development Expenses
8.10.4 Recent strategies and developments:
8.10.4.1 Partnerships, Collaborations, and Agreements:
Unique Offerings 